Indeed, AMPK is a novel molecule that can treat NAFLD and NASH by inhibiting lipogenesis through suppressing SREBP1/2 and upregulating PPARα (Strzyz 2020; Tian et al. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.